StreetInsider.com News Articles

Form 4 Pulsenmore Ltd. For: Oct 14 Filed by: Guz-Lavi Racheli

Wed, 14 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27187300.html

Form 3 Pulsenmore Ltd. For: Oct 06 Filed by: Woods David

Wed, 14 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261014/27187299.html

Form 6-K Pulsenmore Ltd. For: Oct 13

Tue, 13 Oct 2026 07:28:00 -0400

si-local-file:///var/storage/secattach/20261013/27177032.html

Pulsenmore names David Woods as chief commercial officer

Tue, 13 Oct 2026 07:00:41 -0400

Pulsenmore Ltd. (NASDAQ: PLSM, TASE: PLSM) has appointed David Woods as Chief Commercial Officer as the company expands its U.S. commercial operations for its home prenatal ultrasound system.

Woods brings more than 25 years of medical technology experience, most recently serving as CCO at Creo Medical. He previously held senior roles at Pentax Medical, including President and CEO of Pentax Medical Americas.

The Israel-based company received FDA De Novo authorization for its home prenatal ultrasound system and has since launched U.S. commercial operations, including a strategic collaboration with Ouma Health. The system allows pregnant women to perform ultrasound scans at home, with

Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer

Tue, 13 Oct 2026 07:00:00 -0400

Expanded commercial team to accelerate U.S. growth as demand for accessible prenatal care and federal rural health investments create new opportunities

RAMAT GAN, Israel, Oct. 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) ("Pulsenmore" or the "Company"), a pioneer in patient-operated home ultrasound technology, today announced the appointment of David Woods as Chief Commercial Officer

Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer

Tue, 13 Oct 2026 07:00:00 -0400

Expanded commercial team to accelerate U.S. growth as demand for accessible prenatal care and federal rural health investments create new opportunities

Form SCHEDULE 13G Pulsenmore Ltd. Filed by: Aquamarine Financial (Cayman) Ltd

Thu, 08 Oct 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20261008/27167653.html

Form 6-K Pulsenmore Ltd. For: Sep 17

Thu, 17 Sep 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260917/27072652.html

Pulsenmore Expands Its Fertility Platform into the UK

Thu, 17 Sep 2026 07:00:00 -0400

MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company's home ultrasound platform into the UK fertility market where more than 100,000 IVF and fertility treatment cycles were performed in 2024.

OMER, Israel, Sept. 17, 2026 /PRNewswire/ -- Pulsenmore (NASDAQ:

Pulsenmore Expands Its Fertility Platform into the UK

Thu, 17 Sep 2026 07:00:00 -0400

OMER, Israel, Sept. 17, 2026 /PRNewswire/ -- Pulsenmore (NASDAQ:

Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026